| Literature DB >> 24358219 |
Andrew N Luu1, Lorenzo Anez-Bustillos2, Shima Aran2, Francisco J Araiza Arroyo2, Vahid Entezari2, Claudio Rosso3, Brian D Snyder4, Ara Nazarian2.
Abstract
BACKGROUND: High resolution μCT, and combined μPET/CT have emerged as non-invasive techniques to enhance or even replace dual energy X-ray absorptiometry (DXA) as the current preferred approach for fragility fracture risk assessment. The aim of this study was to assess the ability of µPET/CT imaging to differentiate changes in rat bone tissue density and microstructure induced by metabolic bone diseases more accurately than current available methods.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24358219 PMCID: PMC3866175 DOI: 10.1371/journal.pone.0082709
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Study time-line highlighting surgical procedure and measurements.
Figure 2An illustration of the tensile testing mechanism used in the study.
PET/CT based 18FDG and Na18F uptake and bone density values for femurs.
| PET/CT-based Measurements | |||
|---|---|---|---|
| Group | FDG Uptake [%] | NaF Uptake [%] | Bone Density [HU] |
| CON | 68.1 | 100 | 1325 |
|
| 5.3 | - | 24.7 |
| OVX | 70.9 | 95.7 | 1138 |
|
| 6.6 | 6.8 | 17.5 |
| VIT-D | 87.7 | 92.0 | 1090 |
|
| 5.9 | 8.1 | 13.3 |
| P [Group] |
| 0.433 |
|
| P | 0.823 | 0.775 |
|
| P |
| 0.403 |
|
| P |
| 0.775 |
|
P*: P values from Bonferonni post-hoc analysis
* CON NaF values were used as reference (%100) for other groups.
Figure 3CT, PET 18FDG and PET Na18F images from representative animals from CON, OVX and VIT-D groups.
μCT based morphometric indices, mechanical results and DXA based densitometric values for cortical bone specimens.
| uCT-based Measurements | Mechanical Testing-based Measurements | DXA-based Measurements | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | BV/TV [mm3/mm3] | BS/TV [mm3/mm3] | Cort.Th [mm] | App. Density [g/cm3] | Bone Density [g/cm3] | Ult. Strain [mm/mm] | Ult. Strength [MPa] | E [MPa] | Energy to Failure [kJ] | BMC [g] | aBMD [g/cm2] |
| CON | 0.66 | 3.27 | 0.61 | 741.96 | 1110.73 | 0.015 | 24.35 | 1583.14 | 0.12 | 0.151 | 0.191 |
|
|
|
|
|
|
|
|
|
|
| 0.011 | 0.018 |
| OVX | 0.62 | 3.09 | 0.65 | 708.89 | 1098.70 | 0.02 | 15.82 | 869.38 | 0.12 | 0.158 | 0.191 |
|
|
|
|
|
|
|
|
|
|
| 0.013 | 0.019 |
| VIT-D | 0.65 | 3.27 | 0.61 | 729.55 | 1103.12 | 0.01 | 14.40 | 1268.63 | 0.07 | 0.151 | 0.202 |
|
|
|
|
|
|
|
|
|
|
| 0.006 | 0.014 |
| P [Time] |
|
| |||||||||
| P [Group] |
|
|
| 0.150 | 0.150 |
|
|
| 0.140 | 0.992 |
|
| P*: CON-OVX |
| 0.080 | 0.080 | 0.170 | 0.170 | 0.110 |
|
| 0.990 | 0.990 | 0.990 |
| P*: CON-VIT-D | 0.990 | 0.990 | 0.990 | 0.990 | 0.660 | 0.920 |
| 0.180 | 0.280 | 0.990 |
|
| P*:OVX-VIT-D | 0.190 | 0.090 | 0.100 | 0.670 | 0.990 |
| 0.990 |
| 0.230 | 0.990 |
|
P*: P values from Bonferonni post-hoc analysis
μCT based morphometric indices and DXA based densitometric values for cancellous bone specimens.
| uCT-based Measurements | DXA-based Measurements | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | BV/TV [mm3/mm3] | BS/BV [mm2/mm3] | Conn.D. [1/mm3] | SMI | Tb.N [1/mm] | Tb.Th [mm] | Tb.Sp [mm] | Tb.1/N SD | Tb.Th SD | Tb.Sp SD | App. Density [g/cm3] | Bone Density [g/cm3] | DA | BMC | aBMD |
| CON | 0.235 | 34.35 | 110.26 | 1.78 | 4.27 | 0.075 | 0.24 | 0.114 | 0.02 | 0.12 | 316.01 | 927.83 | 1.69 | 0.083 | 0.212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.009 | 0.021 |
| OVX | 0.082 | 34.69 | 24.79 | 2.43 | 1.28 | 0.07 | 0.84 | 0.61 | 0.02 | 0.61 | 144.04 | 927.71 | 1.47 | 0.075 | 0.199 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.006 | 0.016 |
| VIT-D | 0.25 | 29.31 | 92.53 | 1.35 | 3.79 | 0.08 | 0.27 | 0.14 | 0.02 | 0.15 | 338.07 | 932.68 | 1.41 | 0.081 | 0.216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 0.007 | 0.019 |
| P [Time] |
|
| |||||||||||||
| P (ANOVA) |
|
|
|
|
| 0.170 |
|
| 0.720 |
|
| 0.890 |
|
|
|
| P*: CON-OVX |
| 0.990 |
|
|
| 0.990 |
|
| 0.990 |
|
| 0.990 |
|
|
|
| P*: CON-VIT-D | 0.990 | 0.059 | 0.502 |
| 0.590 | 0.220 | 0.990 | 0.990 | 0.990 | 0.990 | 0.810 | 0.990 |
| 0.440 | 0.990 |
| P*:OVX-VIT-D |
| 0.056 |
|
|
| 0.540 |
|
| 0.990 |
|
| 0.990 | 0.990 |
|
|
| 0.99 | |||||||||||||||
P*: P values from Bonferonni post-hoc analysis
† BMD values reported from the last time point
Figure 4DXA-based aBMD changes over the 4 months study period in CON, OVX and VIT-D groups in both trabecular and cortical bone tissues (* indicates significance between CON and OVX groups, ** denotes significance between CON and VIT-D groups, † indicates significance between the OVX and VIT-D groups).
Figure 5Body mass changes over the 4 months study period in CON, OVX and VIT-D groups (* indicates significance between CON and OVX groups, ** denotes significance between CON and VIT-D groups, † indicates significance between the OVX and VIT-D groups).